β-Catenin is a useful adjunct immunohistochemical marker for the diagnosis of pulmonary lymphangioleiomyomatosis

American Journal of Clinical Pathology

Volumn 135, Issue 5, 2011, Pages 776-782

  Flavin, Richard J ^a   Cook, Jennifer ^b   Fiorentino, Michelangelo ^a,c   Bailey, Dyane ^a   Brown, Myles ^b   Loda, Massimo F ^a,b,d  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Catenin; Angiomyolipoma; Immunohistochemistry; Lymphangioleiomyomatosis

Indexed keywords

BETA CATENIN; ESTROGEN RECEPTOR ALPHA; MONOCLONAL ANTIBODY HMB 45; PROGESTERONE RECEPTOR;

ANGIOMYOLIPOMA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPHANGIOLEIOMYOMATOSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY LYMPHANGIOLEIOMYOMATOSIS;

ANGIOMYOLIPOMA; BETA CATENIN; BIOLOGICAL MARKERS; ESTROGEN RECEPTOR ALPHA; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY NEOPLASMS; LUNG NEOPLASMS; LYMPHANGIOLEIOMYOMATOSIS; MELANOCYTES; MUSCLE, SMOOTH, VASCULAR; RECEPTORS, PROGESTERONE; TUBEROUS SCLEROSIS;

EID: 79955038291     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPPC9EX1ZHMRMA     Document Type: Article

References (22)

1. Johnson S. Rare diseases, 1: lymphangioleiomyomatosis: clinical features, management and basic mechanisms. Thorax. 1999;54:254-264. (Pubitemid 29110508)
2. Franz DN, Brody A, Meyer C, et al. Mutational and radiographic analysis of pulmonary disease consistent with lymphangioleiomyomatosis and micronodular pneumocyte hyperplasia in women with tuberous sclerosis. Am J Respir Crit Care Med. 2001;164:661-668. (Pubitemid 32801674)
3. Glasgow CG, Taveira-Dasilva AM, Darling TN, et al. Lymphatic involvement in lymphangioleiomyomatosis. Ann N y Acad Sci. 2008;1131:206-214. (Pubitemid 351758515)
4. Avila NA, Kelly JA, Chu SC, et al. Lymphangioleiomyomatosis: abdominopelvic CT and US findings. Radiology. 2000;216:147-153. (Pubitemid 30434735)
5. Johnson SR, Cordier JF, Lazor R, et al. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J. 2010;35:14-26.
6. Mak BC, Kenerson HL, Aicher LD, et al. Aberrant beta-catenin signaling in tuberous sclerosis. Am J Pathol. 2005;167:107-116. (Pubitemid 40894642)
7. Barnes EA, Kenerson HL, Mak BC, et al. The loss of tuberin promotes cell invasion through the β-catenin pathway [published online ahead of print December 30, 2009]. Am J Respir Cell Mol Biol. 2010;43:617-627. doi:10.1165/rcmb.2008-0335OC.
8. Berger U, Khaghani A, Pomerance A, et al. Pulmonary lymphangioleiomyomatosis and steroid receptors: an immunocytochemical study. Am J Clin Pathol. 1990;93:609-614. (Pubitemid 20151117)
9. Colley MH, Geppert E, Franklin WA. Immunohistochemical detection of steroid receptors in a case of pulmonary lymphangioleiomyomatosis. Am J Surg Pathol. 1989;13:803-807. (Pubitemid 19201952)
10. Ohori NP, Yousem SA, Sonmez-Alpan E, et al. Estrogen and progesterone receptors in lymphangioleiomyomatosis, epithelioid hemangioendothelioma, and sclerosing hemangioma of the lung. Am J Clin Pathol. 1991;96:529-535.
11. Busam KJ, Jungbluth AA. Melan-A, a new melanocytic differentiation marker. Adv Anat Pathol. 1999;6:12-18.
12. Fetsch PA, Fetsch JF, Marincola FM, et al. Comparison of melanoma antigen recognized by T cells (MART-1) to HMB-45: additional evidence to support a common lineage for angiomyolipoma, lymphangiomyomatosis, and clear cell sugar tumor. Mod Pathol. 1998;11:699-703. (Pubitemid 28381601)
13. Hoon V, Thung SN, Kaneko M, et al. HMB-45 reactivity in renal angiomyolipoma and lymphangioleiomyomatosis. Arch Pathol Lab Med. 1994;118:732-734. (Pubitemid 24217606)
14. Matthews TJ, Hornall D, Sheppard MN. Comparison of the use of antibodies to alpha smooth muscle actin and desmin in pulmonary lymphangioleiomyomatosis. J Clin Pathol. 1993;46:479-480. (Pubitemid 23167431)
15. Panizo-Santos A, Sola I, de Alava E, et al. Angiomyolipoma and PEComa are immunoreactive for MyoD1 in cell cytoplasmic staining pattern. Appl Immunohistochem Mol Morphol. 2003;11:156-160. (Pubitemid 36749570)
16. Tanaka H, Imada A, Morikawa T, et al. Diagnosis of pulmonary lymphangioleiomyomatosis by HMB45 in surgically treated spontaneous pneumothorax. Eur Respir J. 1995;8:1879-1882.
17. Bonetti F, Chiodera PL, Pea M, et al. Transbronchial biopsy in lymphangiomyomatosis of the lung: HMB45 for diagnosis. Am J Surg Pathol. 1993;17:1092-1102. (Pubitemid 23313783)
18. D'Armiento J, Imai K, Schiltz J, et al. Identification of the benign mesenchymal tumor gene HMGA2 in lymphangiomyomatosis. Cancer Res. 2007;67:1902-1909. (Pubitemid 46424205)
19. Chilosi M, Pea M, Martignoni G, et al. Cathepsin-k expression in pulmonary lymphangioleiomyomatosis. Mod Pathol. 2009;22:161-166.
20. Hayashi T, Fleming MV, Stetler-Stevenson WG, et al. Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Hum Pathol. 1997;28:1071-1078. (Pubitemid 27388109)
21. Usuki J, Horiba K, Chu SC, et al. Immunohistochemical analysis of proteins of the Bcl-2 family in pulmonary lymphangioleiomyomatosis: association of Bcl-2 expression with hormone receptor status. Arch Pathol Lab Med. 1998;122:895-902. (Pubitemid 28485271)
22. Moon RT, Bowerman B, Boutros M, et al. The promise and perils of Wnt signaling through beta-catenin. Science. 2002;296:1644-1646. (Pubitemid 34579151)